Sickle Cell Anemia Genetics: Beta-Globin Point Mutation & Pathophysiology

Sickle cell disease (preferred over "cell anemia") is caused by a specific point mutation in the HBB gene encoding beta-globin.

Molecular Defect

• Mutation: Single nucleotide substitution (A→T) at codon 6 of exon 1: GAG → GTG.
• Amino Acid Change: Glutamic acid (hydrophilic, negative charge) → Valine (hydrophobic) at position 6 of beta-globin chain.
• Hemoglobin S (HbS): α₂β₂⁶ᵛᵃˡ. Deoxygenated HbS polymerizes into long fibers, distorting RBCs into sickle shapes.

Pathophysiologic Cascade

1. HbS polymerization → RBC rigidity, membrane damage.
2. Hemolysis (intravascular + extravascular) → anemia, bilirubin, LDH↑, haptoglobin↓.
3. Vaso-occlusion → ischemia-reperfusion injury → pain crises, organ damage (spleen, brain, kidneys, lungs, bones).
4. Chronic inflammation, endothelial activation, hypercoagulability.

Genetics & Inheritance

• Autosomal recessive. Homozygous HbSS = sickle cell anemia (most severe).
• Heterozygous HbAS = sickle cell trait (usually asymptomatic; malaria protection).
• Compound heterozygotes: HbSC, HbS/β-thalassemia, HbSD, etc.

Modern Therapies

• Hydroxyurea (induces HbF, reduces polymerization).
• Voxelotor (stabilizes HbS oxygen affinity).
• Crizanlizumab (anti-P-selectin, reduces adhesion).
• Curative: Allogeneic HSCT (matched sibling), Gene therapy (lentiviral βᴬ-T87Q, CRISPR editing).

Newborn screening enables early penicillin prophylaxis, vaccination, and hydroxyurea initiation—transforming survival.